Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gama Explorations, Inc. ( (TSE:SKNY) ) has shared an announcement.
LIR Life Sciences has completed the design of an ex vivo porcine skin study to evaluate whether its novel transdermal agents can enhance skin penetration of large therapeutic macromolecules, ranging from about 5kDa to antibody scale. The controlled study, set to begin in the first quarter of 2026, will compare formulations with and without transdermal agents using confocal microscopy and quantitative fluorescence analysis to measure penetration depth and distribution, with results expected to guide which larger molecules may be suitable for needle-free, skin-applied delivery, potentially strengthening LIR’s position in developing non-injectable obesity therapies and broader large-molecule drug delivery solutions.
More about Gama Explorations, Inc.
LIR Life Sciences Corp. is a life sciences company focused on researching and developing scalable and affordable obesity treatments using novel drug delivery methods. The company is advancing a transdermal patch and other delivery systems that mimic GLP-1, a naturally occurring hormone that regulates appetite and blood sugar, aiming to provide alternatives to injectable drugs and improve access, adherence, and cost-efficiency in both developed and emerging markets.
Average Trading Volume: 119,310
Technical Sentiment Signal: Buy
For detailed information about SKNY stock, go to TipRanks’ Stock Analysis page.